http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. (HealthDay)—Pre-existing antiplatelet use does not seem to be associated with an increased risk of ischemic hemorrhage (ICH), according to an observational study published in the February issue of Academic Emergency Medicine. http://medicalxpress.com/news/2013-03-antiplatelet-drugs-dont-ich.html Cardiology Mon, 25 Mar 2013 14:40:01 EST news283439075 (HealthDay)—Prehospital use of antiplatelet therapy, either aspirin/clopidogrel or dual antiplatelet therapy (DAPT), is associated with a lower incidence of major adverse cardiac events after saphenous vein graft (SVG) intervention, according to research published in the Jan. 15 issue of The American Journal of Cardiology. http://medicalxpress.com/news/2013-01-prehospital-antiplatelets-graft-intervention-outcomes.html Cardiology Mon, 28 Jan 2013 13:20:05 EST news278599665 (HealthDay)—In patients with acute ischemic stroke, aspirin resistance is associated with increased stroke severity and infarct size, according to research published online Nov. 19 in the Archives of Neurology. http://medicalxpress.com/news/2012-11-aspirin-resistance-ups-severity-acute.html Cardiology Wed, 21 Nov 2012 15:10:01 EST news272728841 Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types of stents demonstrated a clinical benefit. Results of the XIMA trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. http://medicalxpress.com/news/2012-10-drug-eluting-stents-benefits-bare-metal-patients.html Cardiology Fri, 26 Oct 2012 13:40:07 EST news270475017 (HealthDay)—In patients receiving drug-eluting stents, dual antiplatelet therapy can be safely discontinued during the first year, according to two studies published online Sept. 19 in the Journal of the American College of Cardiology. http://medicalxpress.com/news/2012-09-duration-antiplatelet-drugs-drug-eluting-stents.html Cardiology Thu, 20 Sep 2012 20:30:02 EST news267382961 Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding, according to results of a trial funded by the National Institutes of Health. Lacunar strokes occur due to chronic high blood pressure and typically produce small lesions deep within the brain. http://medicalxpress.com/news/2012-08-aspirin-clopidogrel-aspirin-patients-lacunar.html Cardiology Wed, 29 Aug 2012 17:00:06 EST news265478144 Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012. http://medicalxpress.com/news/2012-08-global-platelet-reactivity-high-acs.html Cardiology Tue, 28 Aug 2012 11:30:03 EST news265371036 Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012. http://medicalxpress.com/news/2012-08-personalized-antiplatelet-treatment-outcome-pci.html Cardiology Tue, 28 Aug 2012 11:09:49 EST news265370983 Rates of stent thrombosis at three years were low and comparable between zotarolimus-eluting and sirolimus-eluting stents, according to findings from the PROTECT study described here today at ESC Congress 2012. http://medicalxpress.com/news/2012-08-stent-thrombosis-zotarolimus-sirolimus-eluting-stents.html Cardiology Mon, 27 Aug 2012 11:53:09 EST news265287178 According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet. http://medicalxpress.com/news/2012-08-anti-platelet-therapy-cardiac-events-patients.html Cardiology Mon, 27 Aug 2012 10:10:01 EST news265280273 (HealthDay) -- Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor can be used in place of clopidogrel or prasugrel instead of aspirin or as a second antiplatelet agent, according to a report from the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) published online July 16 in Circulation. http://medicalxpress.com/news/2012-07-aspirin-first-line-therapy-unstable-anginanstemi.html Cardiology Tue, 17 Jul 2012 03:31:44 EST news261714695 A study based on more than 1.5 million percutaneous coronary intervention procedures (such as balloon angioplasty or stent placement to open narrowed coronary arteries) suggests that the use of drug-eluting stents varies widely among U.S. physicians, and is only modestly correlated with the patient's risk of coronary artery restenosis (renarrowing), according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication. http://medicalxpress.com/news/2012-07-drug-eluting-stents-varies-widely-modestly.html Cardiology Mon, 09 Jul 2012 16:00:22 EST news261066434 Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of the arteries, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field. http://medicalxpress.com/news/2012-03-class-platelet-blockers-effective-phase.html Cardiology Mon, 26 Mar 2012 09:24:14 EST news251972625 A registry -which includes every patient in Sweden having percutaneous coronary intervention (PCI) for the treatment of acute and stable coronary artery disease- has found that PCI implantations using a new generation of drug-eluting stents is associated with lower rates of relapse (restenosis), stent thrombosis and subsequent mortality than older generation drug-eluting stents and bare-metal stents.(1) http://medicalxpress.com/news/2012-01-real-world-reassuring-scaar-registry.html Cardiology Mon, 09 Jan 2012 04:42:28 EST news245306525 A clinical trial has established the non-inferiority of a drug-eluting stent with a bioabsorbable polymer compared to a drug-eluting stent with a durable polymer. Results of the EVOLVE clinical trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. http://medicalxpress.com/news/2011-11-results-evolve-trial-tct.html Cardiology Fri, 11 Nov 2011 15:17:26 EST news240247032 Non-adherence to antiplatelet therapy – which prevents blood clots following percutaneous coronary intervention (PCI) – was associated with higher rates of both ischemic and bleeding events at 30 days. Results of the PARIS registry were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. http://medicalxpress.com/news/2011-11-results-paris-registry-tct.html Cardiology Wed, 09 Nov 2011 16:10:53 EST news240077442 The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis after 30 days was examined in ADAPT-DES, the largest registry to date to fully examine these relationships. http://medicalxpress.com/news/2011-11-day-results-adapt-des-registry-tct.html Cardiology Wed, 09 Nov 2011 16:10:20 EST news240077411 The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at higher risk, according to results of the DESERT registry. Results of the trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. http://medicalxpress.com/news/2011-11-results-registry-tct.html Cardiology Wed, 09 Nov 2011 16:08:42 EST news240077312 A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome. http://medicalxpress.com/news/2011-08-safety-tolerability-oral-xa-inhibitor.html Cardiology Tue, 30 Aug 2011 11:22:42 EST news233922146 A randomised multicentre open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy is no better than six months DAPT in preventing adverse cardiac events. http://medicalxpress.com/news/2011-08-duration-dual-antiplatelet-therapy-coronary.html Cardiology Tue, 30 Aug 2011 11:17:21 EST news233921782